• Benjamin T Himes, Michael W Ruff, Jaimie J Van Gompel, Sean S Park, Evanthia Galanis, Timothy J Kaufmann, and Joon H Uhm.
• Departments of1Neurological Surgery.
• J. Neurosurg. 2019 Apr 1; 130 (4): 129913031299-1303.

AbstractThe authors present the case of a man with a papillary craniopharyngioma, first diagnosed at 47 years of age, who experienced multiple recurrences. Review of the pathologic specimen from his first resection demonstrated the BRAF V600E mutation. With his most recent recurrence following previous surgery and radiotherapy, at 52 years of age, the decision was made to initiate treatment with the BRAF V600E inhibitor dabrafenib. Imaging following initiation of dabrafenib demonstrated reduction in tumor size. He remained on dabrafenib therapy for approximately 1 year and continued to demonstrate a good clinical result. At that time the decision was made to discontinue dabrafenib therapy and follow up with serial imaging. After more than 1 year of follow-up since stopping dabrafenib, the patient has continued to do well with no radiographic evidence of tumor progression and continues to be monitored with frequent interval imaging.

5 keywords...

hide…